标题：CDC6在不同临床病理分期肝细胞癌中的表达及其对临床预后的影响

      作者：屈耀宁 1，李晓梅 2    1.西安兵器工业五二一医院消化内科，陕西 西安 710065；2.西安航天总医院消化内科，陕西 西安 710100

      卷次： 2023年34卷17期

      【摘要】 目的 探究细胞分裂周期蛋白6 (CDC6)在不同临床病理分期肝细胞癌中的表达水平及其对临床预后的影响。方法 选择2017年1月至2018年2月西安兵器工业五二一医院确诊的78例肝细胞癌(LIHC)患者作为LIHC组，另选择同期在医院治疗的50例肝脏良性病变患者作为对照组。分别采集LIHC组患者的肝细胞癌组织和对照组患者的正常肝脏组织检测其CDC6蛋白阳性表达及mRNA表达量。比较LIHC组和对照组、LIHC组不同临床病理特征患者的 CDC6 蛋白阳性表达及 mRNA 表达量，采用 Kaplan-Meier 法对不同 CDC6 蛋白表达和CDC6mRNA表达LIHC患者进行生存分析，并就不同CDC6蛋白表达和CDC6 mRNA表达LIHC患者的预后情况进行比较。结果 LIHC组患者的CDC6蛋白阳性表达率为73.08% (57/78)，明显高于对照组的6.00% (3/50)，差异有统计学意义(P<0.05)；LIHC组患者的CDC6 mRNA表达量为1.68±0.25，明显高于对照组的 1.42±0.22，差异有统计学意义(P<0.05)。LIHC组患者中，淋巴结转移、TNMⅠ~Ⅱ期、中低分化和脉管浸润患者的CDC6 mRNA表达量水平明显高于未发现淋巴结转移、TNM Ⅲ~Ⅳ期、高分化和未发现脉管浸润的患者，差异均有统计学意义(P<0.05)。淋巴结转移、TNMⅠ~Ⅱ期、中低分化和脉管浸润患者的CDC6蛋白阳性表达率明显高于未发现淋巴结转移、TNM Ⅲ~Ⅳ期、高分化和未发现脉管浸润的患者，差异均有统计学意义(P<0.05)。LIHC组中CDC6阳性表达患者的无进展生存期(DFS)和总生存期(OS)分别为(40.56±4.26)个月、(54.12±8.23)个月，明显低于CDC6阴性表达患者的(46.57±6.16)个月、(65.73±9.44)个月，差异均具有统计学意义(P<0.05)。Kaplan-Meier曲线结果表明，高CDC6mRNA表达患者的OS为(56.36±7.23)个月，明显低于低表达患者的(63.47±8.16)个月，差异有统计学意义(P<0.05)。结论 CDC6表达影响LIHC患者的临床病理特征及预后，CDC6表达高的患者预后较差，可将其作为LIHC治疗的潜在靶点及预后生物标志物应用于临床。
      【关键词】 细胞分裂周期蛋白6；肝细胞癌；mRNA表达量；临床病理特征；预后
      【中图分类号】 R735.7 【文献标识码】 A 【文章编号】 1003—6350（2023）17—2438—05

Expression of CDC6 in hepatocellular carcinoma with different clinicopathological stages and its influence onclinical prognosis.
QU Yao-ning 1, LI Xiao-mei 2. 1. Department of Gastroenterology, 521 Hospital of Xi'an OrdnanceIndustry, Xi'an 710065, Shaanxi, CHINA; 2. Department of Gastroenterology, Xi'an Aerospace General Hospital, Xi'an710100, Shaanxi, CHINA
【Abstract】 Objective To research the expression of cell division cycleprotein 6 (CDC6) in hepatocellular carci-noma with different clinicopathological stages and its influence on clinical prognosis. Methods Seventy-eight patientswith liver hepatocellular carcinoma (LIHC) diagnosed in 521 Hospital of Xi'an Ordnance Industry from January 2017 toFebruary 2018 were selected as the LIHC group, and 50 patients with benign liver lesions treated in the hospital duringthe same period were selected as the control group. Hepatocellular carcinoma tissues of patients in LIHC group and nor-mal liver tissues of patients in control group were collected to detect the positive expression of CDC6 protein and mRNAexpression. The positive expression of CDC6 protein and mRNA in patients with different clinicopathological features inLIHC group were compared with those in control group and LIHC group. Kaplan-Meier method was used to analyze thesurvival of patients with different CDC6 protein expression and CDC6 mRNA expression, and the prognosis of patientswith different CDC6 protein expression and CDC6 mRNA expression was compared. Results The positive expressionrate of CDC6 protein in LIHC group was 73.08% (57/78), which was significantly higher than 6.00% (3/50) in the con-trol group (P<0.05). The expression of CDC6 mRNA in LIHC group was 1.68±0.25, which was significantly higher than1.42 ±0.22 in the control group (P<0.05). In the LIHC group, the expression level of CDC6 mRNA in patients withlymph node metastasis, TNMⅠ-Ⅱ stage, moderate-low differentiation, and vascular infiltration was significantly higherthan that in patients without lymph node metastasis, TNMⅢ-Ⅳ stage, high differentiation, and vascular infiltration, re-spectively (P<0.05). The positive expression rates of CDC6 protein in patients with lymph node metastasis, TNMⅠ-Ⅱstage, moderate-low differentiation, and vascular infiltration were significantly higher than those in patients without lymphnode metastasis, TNM Ⅲ -Ⅳ stage, high differentiation, and vascular infiltration, respectively (P<0.05). In the LIHCgroup, the progression-free survival (DFS) and overall survival (OS) of CDC6 positive patients were (40.56±4.26) monthsand (54.12±8.23) months, respectively, significantly lower than (46.57±6.16) months and (65.73±9.44) months of CDC6negative patients (P<0.05). Kaplan-Meier curve showed that the OS of patients with high CDC6 mRNA expression was(63.47±8.16) months, significantly lower than (56.36±7.23) months of patients with low CDC mRNA expression (P<0.05). Conclusion The expression of CDC6 affects the clinical pathological characteristics and prognosis of LIHC pa-tients. Patients with high expression of CDC6 have poor prognosis and can be used as potential targets and prognosticbiomarkers for LIHC treatment in clinical practice.
      【Key words】 Cell division cycleprotein 6; Liver hepatocellular carcinoma; mRNA expression level; Clinicopatho-logical features; Prognosis